United States Leads Global Pancreatic Cancer Market with 50% Share, Surpassing EU4, UK, and Japan, Reports DelveInsight | AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, Celgene, BMS

As per DelveInsight, the Pancreatic Cancer Market is anticipated to grow immensely in the coming years owing to the launch of upcoming therapies and the increase in the incident population of Pancreatic Cancer in the 7MM.
DelveInsight's "Pancreatic Cancer Market Insights, Epidemiology, and Market Forecast 2034 [https://www.delveinsight.com/report-store/pancreatic-cancer-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Pancreatic Cancer market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Pancreatic Cancer market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Key highlights from the Pancreatic Cancer Market Report [https://www.delveinsight.com/report-store/pancreatic-cancer-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]:

*
Key players such as Alligator Bioscience and Actuate Therapeutics, among others, are advancing their lead candidates through various stages of clinical development, aiming to explore new treatments for pancreatic cancer.

*
In 2023, the United States represented nearly 50% of the total pancreatic cancer market size across the 7MM. By 2034, LYNPARZA (olaparib) is projected to capture a significant share of the market in these regions. Japan holds the second-largest market share in the 7MM during the forecast period of 2024-2034.

*
The pancreatic cancer market is expected to expand throughout the forecast period (2024-2034), driven by rising incidence rates, advancements in early diagnosis, and the introduction of new and more effective therapies.

*
Pancreatic cancer is one of the deadliest cancers globally and predominantly affects men more than women. It is categorized into two main types: exocrine pancreatic cancer, including adenocarcinoma, and neuroendocrine pancreatic cancer.

*
In terms of market size, the United States holds the largest share, accounting for approximately 50% of the global pancreatic cancer market, compared to the EU4 countries (Germany, Spain, Italy, France), the United Kingdom, and Japan.

*
Among the approved treatments, LYNPARZA (olaparib) is expected to capture the largest market share in the United States. Approved by the US FDA in 2019 for patients with BRCA mutations, LYNPARZA (olaparib) is a key player in the treatment landscape. Additionally, VITRAKVI (larotrectinib) and ROZLYTREK (entrectinib) are approved for patients with NTRK gene expression, while KEYTRUDA (pembrolizumab) is approved for patients with microsatellite instability-high tumors.

*
In January 2024, Alligator Bioscience reported promising results from the OPTIMIZE-1 Phase II study of its lead asset, mitazalimab, for first-line metastatic pancreatic cancer. The study met its primary endpoint, showing a confirmed objective response rate (ORR) of 40.4%, an unconfirmed ORR of 50.9%, and a disease control rate (DCR) of 79% among 57 evaluable patients, according to the response evaluation criteria in solid tumors.

*
Key pancreatic cancer companies working in the pancreatic cancer market are AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, Celgene, Bristol Myers Squibb, BioLineRx, Alligator Bioscience, Bellicum Pharmaceuticals, OSE Immunotherapeutics, Actuate Therapeutics, FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, Merus, Mirati Therapeutics, Rexahn Pharmaceuticals, Ocuphire Pharma, Processa Pharmaceuticals, ImmunityBio, Berg, Panbela Therapeutics, GlaxoSmithKline, Eleison Pharmaceuticals, Molecular Templates, Lokon Pharma AB, Cantargia AB, Bristol-Myers Squibb, and others.

*
The pipeline for pancreatic cancer treatments is robust, with significant contributions from key players such as Alligator Bioscience and Actuate Therapeutics, advancing into mid-stage clinical trials.

Read detailed insights on Pancreatic Cancer market outlook 2034 @ https://www.delveinsight.com/sample-request/pancreatic-cancer-market [https://www.delveinsight.com/sample-request/pancreatic-cancer-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Pancreatic Cancer Overview

Pancreatic cancer originates in the tissues of the pancreas, an abdominal organ located behind the lower part of the stomach. The pancreas plays a crucial role in digestion by releasing enzymes and regulating blood sugar levels through hormone production. Pancreatic cancer involves the formation of malignant cells within the pancreas. This disease can lead to both cancerous and noncancerous tumors, with the most common form being pancreatic ductal adenocarcinoma, which starts in the cells lining the ducts that transport digestive enzymes.

Diagnosing pancreatic cancer involves a thorough review of the patient's medical history, a physical exam, and imaging tests such as CT scans, MRIs, and endoscopic ultrasounds. To confirm cancer, procedures like fine needle aspiration (FNA) or surgical biopsy are used, along with additional blood tests and PET scans to assess cancer spread and guide treatment.

Surgery is an option for about 20% of pancreatic cancer patients, as most cases are detected at an advanced stage. When surgery is possible, it is often combined with systemic therapy and/or radiation therapy, either as adjuvant therapy post-surgery or as neoadjuvant therapy to shrink the tumor before surgery.

Chemotherapy options include XELODA (capecitabine), 5-FU (fluorouracil), GEMZAR (gemcitabine), and CAMPTOSAR (irinotecan). Targeted therapies like TARCEVA (erlotinib) are FDA-approved for advanced pancreatic cancer in combination with gemcitabine, while LYNPARZA (olaparib) is approved for metastatic pancreatic cancer with a germline BRCA mutation.

Pancreatic Cancer Epidemiology Assessment

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries from 2020 to 2034. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.

Pancreatic Cancer Epidemiology Insights:

*
According to estimates from DelveInsight, the United States accounted for approximately 35% of the total incident cases of pancreatic cancer in 2023. The 2023 analysis reveals that distant-stage pancreatic cancer cases were the most prevalent, representing nearly 50% of cases, followed by regional and localized stages.

*
In 2023, the United States had the highest incidence of pancreatic cancer among the 7MM, representing about 35% of the total cases, followed by Japan with nearly 25% of the cases.

*
Key genetic mutations associated with pancreatic cancer include KRAS2, TP53, SMAD4/DPC4, BRCA1/2, MSI-H/dMMR, and NTRK. In 2023, KRAS2 and TP53 were the most commonly identified mutations in pancreatic cancer cases in the United States.

*
Among the EU4 countries and the UK, Germany reported the highest number of incident cases of pancreatic cancer in 2023, followed by France.

Pancreatic Cancer Marketed Drugs

*
LYNPARZA (olaparib): AstraZeneca

*
KEYTRUDA (pembrolizumab): Merck Sharp & Dohme

Pancreatic Cancer Emerging Drugs

*
Mitazalimab (ADC-1013): Alligator Bioscience

*
Elraglusib (9 ING 41): Actuate Therapeutics

Learn How the Pancreatic Cancer Market Will Evolve and Grow by 2034 @ https://www.delveinsight.com/report-store/pancreatic-cancer-market [https://www.delveinsight.com/report-store/pancreatic-cancer-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Pancreatic Cancer Market Outlook

LYNPARZA (olaparib) is a pioneering PARP inhibitor and the first targeted therapy designed to disrupt the DNA damage response (DDR) in tumors with homologous recombination repair deficiencies, such as those with BRCA1 or BRCA2 mutations. In December 2019, AstraZeneca announced that LYNPARZA had received approval from the US FDA for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma who have not experienced disease progression after at least 16 weeks of first-line platinum-based chemotherapy.

KEYTRUDA (pembrolizumab) is an anti-PD-1 therapy that enhances the immune system's ability to detect and combat tumor cells. In May 2017, Merck reported that the US FDA had approved KEYTRUDA for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors exhibiting microsatellite instability-high (MSI-H) or mismatch repair deficiency that have progressed after prior treatments and who have no other satisfactory treatment options.

Leading Players in the Pancreatic Cancer Therapeutics Market Include:

Pancreatic Cancer Companies working in the market are AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, Celgene, Bristol Myers Squibb, BioLineRx, Alligator Bioscience, Bellicum Pharmaceuticals, OSE Immunotherapeutics, Actuate Therapeutics, FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, Merus, Mirati Therapeutics, Rexahn Pharmaceuticals, Ocuphire Pharma, Processa Pharmaceuticals, ImmunityBio, Berg, Panbela Therapeutics, GlaxoSmithKline, Eleison Pharmaceuticals, Molecular Templates, Lokon Pharma AB, Cantargia AB, and others.

Pancreatic Cancer Report Covers the In-depth Assessment of the Emerging Pancreatic Cancer Drugs & Key Companies. Download the Pancreatic Cancer Market Sample Report to Learn More @ https://www.delveinsight.com/sample-request/pancreatic-cancer-market [https://www.delveinsight.com/sample-request/pancreatic-cancer-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Contents

1. Key Insights

2. Executive Summary

3. Pancreatic Cancer Competitive Intelligence Analysis

4. Pancreatic Cancer Market Overview at a Glance

5. Pancreatic Cancer Disease Background and Overview

6. Pancreatic Cancer Patient Journey

7. Pancreatic Cancer Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Pancreatic Cancer Treatment Algorithm, Current Treatment, and Medical Practices

9. Pancreatic Cancer Unmet Needs

10. Key Endpoints of Pancreatic Cancer Treatment

11. Pancreatic Cancer Marketed Products

12. Pancreatic Cancer Emerging Drugs and Latest Therapeutic Advances

13. Pancreatic Cancer Seven Major Market Analysis

14. Attribute Analysis

15. Pancreatic Cancer Market Outlook (In US, EU5, and Japan)

16. Pancreatic Cancer Access and Reimbursement Overview

17. KOL Views on the Pancreatic Cancer Market

18. Pancreatic Cancer Market Drivers

19. Pancreatic Cancer Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Trending Reports by DelveInsight:

Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=united-states-leads-global-pancreatic-cancer-market-with-50-share-surpassing-eu4-uk-and-japan-reports-delveinsight-astrazeneca-merck-sharp-dohme-llc-bayer-roche-celgene-bms]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.